Viridian Therapeutics (1S1) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1S1 Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Viridian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1S1 Stock 12 Month Forecast

Average Price Target

€30.44

▲(47.77% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is €30.44 with a high forecast of €36.59 and a low forecast of €19.63. The average price target represents a 47.77% change from the last price of €20.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","37":"€37","16.75":"€16.75","23.5":"€23.5","30.25":"€30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.58757508,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€36.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.44006924,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.63235736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16.75,23.5,30.25,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,19.614428852307693,21.028857704615383,22.443286556923077,23.85771540923077,25.27214426153846,26.686573113846155,28.101001966153845,29.51543081846154,30.929859670769233,32.344288523076926,33.75871737538462,35.173146227692314,{"y":36.58757508,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,19.141543787692306,20.083087575384614,21.02463136307692,21.96617515076923,22.90771893846154,23.849262726153846,24.790806513846153,25.73235030153846,26.67389408923077,27.615437876923075,28.556981664615385,29.498525452307693,{"y":30.44006924,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,18.310181335384616,18.42036267076923,18.530544006153846,18.64072534153846,18.750906676923076,18.861088012307693,18.971269347692306,19.081450683076923,19.19163201846154,19.301813353846153,19.41199468923077,19.522176024615383,{"y":19.63235736,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.995,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.485,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€36.59

Average Price Target€30.44

Lowest Price Target€19.63

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

€27.66

Buy

34.29%

Upside

Assigned

10/14/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Revolution Medicines (NASDAQ: RVMD) and Viridian Therapeutics (NASDAQ: VRDN)

Lisa Walter

RBC Capital

€33.91

Buy

64.61%

Upside

Reiterated

10/08/26

RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Rami Katkhuda

LifeSci Capital

€31.23

Buy

51.62%

Upside

Reiterated

10/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Teladoc (NYSE: TDOC) and Protagonist Therapeutics (NASDAQ: PTGX)

Richard Law CFA

Goldman Sachs

€34.8→€35.7

Buy

73.28%

Upside

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Viridian Therapeutics (NASDAQ: VRDN)

Alex Thompson CFA

Stifel Nicolaus

€35.7

Buy

73.28%

Upside

Reiterated

08/13/26

Stifel Nicolaus Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Gavin Clark-Gartner

Evercore ISI

€23.2

Buy

12.63%

Upside

Reiterated

08/10/26

Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI

Douglas Tsao

H.C. Wainwright

€19.63

Buy

-4.70%

Downside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/26

Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart

Laura Chico

Wedbush

€38.37→€36.59

Buy

77.61%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)

Serge Belanger

Needham

€30.34

Buy

47.29%

Upside

Reiterated

08/06/26

Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA) and Viridian Therapeutics (NASDAQ: VRDN)

Faisal Khurshid

Jefferies

€26.77

Buy

29.96%

Upside

Reiterated

06/30/26

Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst

Thomas Smith

Leerink Partners

€44.62

Buy

116.60%

Upside

Reiterated

04/06/26

Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease

Michael Yee

UBS

€44.62

Buy

116.60%

Upside

Initiated

01/07/26

Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

€27.66

Buy

34.29%

Upside

Assigned

10/14/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Revolution Medicines (NASDAQ: RVMD) and Viridian Therapeutics (NASDAQ: VRDN)

Lisa Walter

RBC Capital

€33.91

Buy

64.61%

Upside

Reiterated

10/08/26

RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Rami Katkhuda

LifeSci Capital

€31.23

Buy

51.62%

Upside

Reiterated

10/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Teladoc (NYSE: TDOC) and Protagonist Therapeutics (NASDAQ: PTGX)

Richard Law CFA

Goldman Sachs

€34.8→€35.7

Buy

73.28%

Upside

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Viridian Therapeutics (NASDAQ: VRDN)

Alex Thompson CFA

Stifel Nicolaus

€35.7

Buy

73.28%

Upside

Reiterated

08/13/26

Stifel Nicolaus Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Gavin Clark-Gartner

Evercore ISI

€23.2

Buy

12.63%

Upside

Reiterated

08/10/26

Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI

Douglas Tsao

H.C. Wainwright

€19.63

Buy

-4.70%

Downside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/26

Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart

Laura Chico

Wedbush

€38.37→€36.59

Buy

77.61%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)

Serge Belanger

Needham

€30.34

Buy

47.29%

Upside

Reiterated

08/06/26

Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA) and Viridian Therapeutics (NASDAQ: VRDN)

Faisal Khurshid

Jefferies

€26.77

Buy

29.96%

Upside

Reiterated

06/30/26

Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst

Thomas Smith

Leerink Partners

€44.62

Buy

116.60%

Upside

Reiterated

04/06/26

Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease

Michael Yee

UBS

€44.62

Buy

116.60%

Upside

Initiated

01/07/26

Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

EHCEncompass Health

MDWDMediwound

OVIDOvid Therapeutics

ARDXArdelyx

STOKStoke Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

3 Months

Alex Thompson CFAStifel Nicolaus

Success Rate

12/18 ratings generated profit

Average Return

+8.88%

Copying Alex Thompson CFA's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.88% per trade.

1 Year

Alex Thompson CFAStifel Nicolaus

Success Rate

12/18 ratings generated profit

Average Return

+14.71%

Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +14.71% per trade.

2 Years

Douglas TsaoH.C. Wainwright

Success Rate

14/22 ratings generated profit

Average Return

+13.59%

Copying Douglas Tsao's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +13.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1S1 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1S1 has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1S1 average Analyst price target in the past 3 months is 30.44.

Each month's total comprises the sum of three months' worth of ratings.

1S1 Financial Forecast

1S1 Earnings Forecast

Next quarter’s earnings estimate for 1S1 is -€0.91 with a range of -€1.12 to -€0.70. The previous quarter’s EPS was -€0.94. 1S1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1S1 has Performed in-line its overall industry.

1S1 Sales Forecast

Next quarter’s sales forecast for 1S1 is €4.18M with a range of €0.00 to €13.39M. The previous quarter’s sales results were €253.44K. 1S1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1S1 has Performed in-line its overall industry.

1S1 Stock Forecast FAQ

What is DE:1S1’s average 12-month price target, according to analysts?

Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 30.44.

What is DE:1S1’s upside potential, based on the analysts’ average price target?

Viridian Therapeutics has 47.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Viridian Therapeutics a Buy, Sell or Hold?

Viridian Therapeutics has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Viridian Therapeutics’s share price target?

The average share price target for Viridian Therapeutics is 30.44. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €36.59 ,and the lowest forecast is €19.63. The average share price target represents 47.77% Increase from the current price of €20.6.

What do analysts say about Viridian Therapeutics?

Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Viridian Therapeutics?

To buy shares of DE:1S1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Viridian Therapeutics (1S1) Stock Forecast & Price Target

1S1 Analyst Ratings

1S1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viridian Therapeutics

1S1 Analyst Recommendation Trends

1S1 Financial Forecast

1S1 Earnings Forecast

1S1 Sales Forecast

1S1 Stock Forecast FAQ

Detailed List of Analyst Forecasts